Clinical outcomes and mechanism of action for rheopheresis treatment of age‐related macular degeneration (AMD)

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of clinical apheresis

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jca.20047PMID 15892078
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Missense variations in the fibulin 5 gene and age-related macular degeneration.

  2004cited by this paper
• Ultrastructural aging of the RPE-Bruch's membrane-choriocapillaris complex in the D-galactose-treated mouse.

  2004cited by this paper
• Current concepts in the pathogenesis of age-related macular degeneration.

  2004cited by this paper
• Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) Is a Binding Partner of Epithelial Growth Factor-containing Fibulin-like Extracellular Matrix Protein 1 (EFEMP1)

  2004cited by this paper
• Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.

  2004cited by this paper
• Association between C-reactive protein and age-related macular degeneration.

  2004cited by this paper
• VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection

  2004cited by this paper
• Sorsby fundus dystrophy mutation Timp3S156C affects the morphological and biochemical phenotype but not metalloproteinase homeostasis

  2003cited by this paper
• Rheopheresis in Patients with Ischemic Diabetic Foot Syndrome: Results of an Open Label Prospective Pilot Trial

  2003cited by this paper
• Optical coherence tomography of fundus abnormalities associated with type II membranoproliferative glomerulonephritis.

  2003cited by this paper
• Carboxyethylpyrrole Protein Adducts and Autoantibodies, Biomarkers for Age-related Macular Degeneration*

  2003cited by this paper
• Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine.

  2003cited by this paper
• Age-related alterations in the diffusional transport of amino acids across the human Bruch's-choroid complex.

  2002cited by this paper
• Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis.

  2002cited by this paper
• Analysis of the collagen VI assemblies associated with Sorsby's fundus dystrophy.

  2002cited by this paper
• The Treatment of Age-Related Macular Degeneration (ARMD) with Etracorporeal Treatment Procedures. A Follow-up of Four Years

  2002cited by this paper
• PULSATILE OCULAR BLOOD FLOW IN ASYMMETRIC EXUDATIVE AGE-RELATED MACULAR DEGENERATION

  2002cited by this paper
• The effect of age on the macromolecular permeability of human Bruch's membrane.

  2001cited by this paper
• An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration.

  2001cited by this paper
• Pulsatile ocular blood flow in asymmetric exudative age related macular degeneration

  2001cited by this paper
• Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction.

  2001cited by this paper
• Ocular perfusion and age-related macular degeneration.

  2001cited by this paper
• A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.

  2001cited by this paper
• INFLUENCE OF MEMBRANE DIFFERENTIAL FILTRATION ON THE NATURAL COURSE OF AGE‐RELATED MACULAR DEGENERATION: A Randomized Trial

  2000cited by this paper
• Pigment-epithelium-derived factor--a key coordinator of retinal neuronal and vascular functions.

  2000cited by this paper
• Influence of membrane differential filtration on the natural course of age-related macular degeneration: a randomized trial.

  2000cited by this paper
• A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy

  1999influential reference
• A hemodynamic model of the pathogenesis of age-related macular degeneration.

  1997influential reference
• Clinical efficacy of haemorheological treatment using plasma exchange, selective adsorption and membrane differential filtration in maculopathy, retinal vein occlusion and uveal effusion syndrome.

  1996cited by this paper
• Change in Hemorrheological and Biochemical Parameters following Membrane Differential Filtration

  1995cited by this paper
• Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectin.

  1995cited by this paper
• Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy

  1994cited by this paper
• Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein.

  1993cited by this paper
• In vitro studies on shedding and phagocytosis of rod outer segments in the rat retina: effect of oxygen concentration.

  1982cited by this paper

• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

  2023cites this paper
• Therapeutic Plasmapheresis: A Revision of Literature

  2022cites this paper
• Rheopheresis: A narrative review

  2022cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

  2019cites this paper
• Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review.

  2018cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

  2016cites this paper
• Design and development of a novel artificial Bruch's membrane for ocular-based therapies

  2016cites this paper
• Complement pathway biomarkers and age-related macular degeneration

  2016cites this paper
• Introduction to Special Issue: Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 7th Edition

  2016cites this paper
• Assessing the Suitability of Electrospun Poly(Ethylene Terephthalate) and Polystyrene as Cell Carrier Substrates for Potential Subsequent Implantation as a Synthetic Bruch's Membrane

  2015cites this paper
• Preservation of the Photoreceptor Inner/Outer Segment Junction in Dry Age-Related Macular Degeneration Treated by Rheohemapheresis

  2015cites this paper
• Update on current and future novel therapies for dry age-related macular degeneration

  2013cites this paper
• Rheopheresis and Pathology of the Microcirculation

  2013cites this paper
• Lipoprotein apheresis--more than just cholesterol reduction?

  2013cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue

  2013cites this paper
• Lipoprotein apheresis standard for apheresis competence centers--an updated synthesis and amendment to pre-existing standards.

  2013cites this paper
• Erratum: Special issue: Clinical applications of therapeutic apheresis: An evidence based approach. 5th edition

  2010cites this paper
• Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis

  2010cites this paper
• Ein Methodenkonzept zur Parametrisierung der Perfusionshomogenität : Therapiekontrolle der altersabhängigen Makuladegeneration

  2010cites this paper
• Acute and Subacute Effect of Rheopheresis on Microvascular Endothelial Function in Patients Suffering From Age‐related Macular Degeneration

  2009cites this paper
• Plasmapheresis for dry age-related macular degeneration--evidence based?

  2009cites this paper
• Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center).

  2009cites this paper
• Effects of Fibrinogen and α2‐Macroglobulin and Their Apheretic Elimination on General Blood Rheology and Rheological Characteristics of Red Blood Cell Aggregates

  2008cites this paper
• Update on multi-center clinical trials in the United States.

  2007cites this paper
• Rheopheresis in Vascular Diseases

  2007cites this paper
• Effekte der LDL-Apherese - Mehr als nur Cholesterinsenkung?

  2007cites this paper
• Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for apheresis

  2007cites this paper
• [Effects of LDL-apheresis--more than reduction of cholesterol?].

  2007cites this paper
• A Study of Quality of Life in Age–Related Macular Degeneration Comparing Photodynamic Therapy and Pegaptanib Sodium Treatment Groups

  2006cites this paper
• Quality of Life in Macular Degeneration Between Photodynamic Therapy and Pegaptanib Treatment Groups

  2006cites this paper
• Treatment of nonexudative (dry) age-related macular degeneration

  2006cites this paper
• A 76-year-old man with macular degeneration.

  2006cites this paper
• Tissue Inhibitor of Metalloproteinase-3 Plays Important Roles in the Kidney Following Unilateral Ureteral Obstruction

  2006cites this paper
• Evidence‐based apheresis

  2005cites this paper
• Therapeutic Apheresis—State of the Art in the Year 2005

  2005cites this paper
• Investigations of a possible link between age-related macular degeneration and atherosclerosis.

  2005cites this paper